MENU
Top
Technology
Join Our Team
Company/Contact
News
JPN
2022.12.28
AMED to Provide Thyas $7.2 Million (JPY 950 Million) Grant for World's First Clinical Trial of iPSC-Derived Killer T Cell Therapy
2022.12.20
Thyas Enters into Joint Research Agreement and Exclusive License for Data and Patents of Clinical Manufacturing of iPSC-Derived CAR-NK Cells
2022.12.13
Dr. Shin Kaneko published a new article in Nature Biomedical Engineering.
2022.12.07
Thyas’ article on “Nature Milestone: T cells" - "Leading the next wave of cancer immune-cell therapies via allogeneic iPS-Ts."
2022.10.01
Thyas opened Shonan office
2022.02.28
Thyas Co. Ltd., a Kyoto University spin-off, Closes JPY 2.1B Series B Financing from Eight Roads Ventures/F-Prime to Develop Novel iPSC-derived Immune Cell Platform
2021.11.12
Change of board structure
2021.11.12
Announcement of Series A3 financing
2021.09.01
Joint research on personalized cancer immunotherapy using regenerated T cells derived from iPS cells
2021.05.18
Dr. Shin Kaneko published a new article in Nature Biomedical Engineering.
1
2
>